[go: up one dir, main page]

EA200970700A1 - Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний - Google Patents

Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний

Info

Publication number
EA200970700A1
EA200970700A1 EA200970700A EA200970700A EA200970700A1 EA 200970700 A1 EA200970700 A1 EA 200970700A1 EA 200970700 A EA200970700 A EA 200970700A EA 200970700 A EA200970700 A EA 200970700A EA 200970700 A1 EA200970700 A1 EA 200970700A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
diseases
fusion proteins
diseases caused
kinase
Prior art date
Application number
EA200970700A
Other languages
English (en)
Inventor
Дэниел Л. Флинн
Питер А. Петилло
Майкл Д. Кауфман
Original Assignee
ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA200970700A1 publication Critical patent/EA200970700A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Соединения в соответствии с данным изобретением находят применение в лечении рака млекопитающих, особенно рака человека, включающего, но не ограниченного ими, злокачественные меланомы, солидные опухоли, глиобластомы, рак яичников, рак поджелудочной железы, рак простаты, раки легких, раки молочной железы, раки почек, печеночные раки, карциномы шейки матки, метастазы первичных мест опухоли, миелопролиферативные заболевания, хронический миелогенный лейкоз, папиллярную карциному щитовидной железы, немелкоклеточный рак легких, мезотелиому, гиперэозинофильный синдром, желудочно-кишечные стромальные опухоли, раки прямой кишки, глазные заболевания, характеризуемые гиперпролиферацией, ведущей к слепоте, включая различные ретинопатии, диабетическую ретинопатию, ревматоидный артрит, астму, хроническое обструктивное заболевание легких, мастоцитоз, лейкоз мастоцитов, заболевания, вызываемые с-Abl киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами, заболевания, вызываемые c-Kit киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами, заболевания, вызываемые c-Met киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами, или заболевания, вызываемые Raf киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами.
EA200970700A 2007-04-20 2008-04-18 Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний EA200970700A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91321607P 2007-04-20 2007-04-20
PCT/US2008/060896 WO2008131276A1 (en) 2007-04-20 2008-04-18 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases

Publications (1)

Publication Number Publication Date
EA200970700A1 true EA200970700A1 (ru) 2010-02-26

Family

ID=39872877

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970700A EA200970700A1 (ru) 2007-04-20 2008-04-18 Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний

Country Status (14)

Country Link
US (4) US20080269254A1 (ru)
EP (5) EP2481736A1 (ru)
JP (2) JP2010524970A (ru)
KR (2) KR20100017184A (ru)
CN (2) CN101801383A (ru)
AU (4) AU2008242697A1 (ru)
BR (2) BRPI0807717A2 (ru)
CA (4) CA2684950A1 (ru)
EA (1) EA200970700A1 (ru)
IL (1) IL201650A0 (ru)
MX (2) MX2009011343A (ru)
RU (1) RU2009142851A (ru)
SG (1) SG183054A1 (ru)
WO (4) WO2008140895A1 (ru)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
WO2008140895A1 (en) * 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EA201170627A1 (ru) * 2008-10-29 2011-10-31 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
EP2473501B1 (en) * 2009-09-03 2019-02-20 Allergan, Inc. Compounds as tyrosine kinase modulators
WO2011062955A2 (en) * 2009-11-18 2011-05-26 University Of Massachusetts Compounds for modulating tlr2
CA2781685C (en) 2009-12-11 2018-09-04 Autifony Therapeutics Limited Imidazolidinedione derivatives
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
KR20130091331A (ko) * 2010-07-16 2013-08-16 교와 핫꼬 기린 가부시키가이샤 함질소 방향족 복소환 유도체
US20130165475A1 (en) * 2010-09-01 2013-06-27 Ascepion Pharmaceuticals, Inc. Deuterium-enriched heterocyclic compounds as kinase inhibitors
CN102408408A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物
CN102432592A (zh) * 2010-09-29 2012-05-02 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物及其制备方法
PL2649066T3 (pl) 2010-12-06 2017-04-28 Autifony Therapeutics Limited Pochodne hydantoiny przydatne jako inhibitory KV3
WO2012078673A1 (en) * 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
CN102532113B (zh) * 2010-12-22 2014-09-10 北大方正集团有限公司 芳基脲衍生物
CN102558144A (zh) * 2010-12-22 2012-07-11 北大方正集团有限公司 一种芳基脲衍生物
KR20120100027A (ko) * 2011-03-02 2012-09-12 한국생명공학연구원 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물
SMT201700035T1 (it) 2011-05-13 2017-03-08 Array Biopharma Inc Composti di pirrolidinil urea, pirrolidinil tiourea e pirrolidinil guanidina come inibitori di chinasi trka
BR112013031402A2 (pt) 2011-06-07 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
EP2852589B1 (en) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2875014B1 (en) * 2012-07-17 2017-11-29 Washington University Anti-mucus drugs and uses therefor
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
KR102181915B1 (ko) 2012-11-13 2020-11-23 어레이 바이오파마 인크. Trka 키나아제 억제제로서 n-피롤리디닐, n'-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
BR112015011010B1 (pt) 2012-11-13 2023-03-07 Array Biopharma Inc Compostos de ureia bicíclica, tioureia, guanidina e cianoguanidina, seus usos, seus processos de preparação e composições farmacêuticas que os compreendem
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CN106986857B (zh) 2013-02-19 2019-07-05 小野药品工业株式会社 Trk抑制化合物
CA2903081A1 (en) * 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
ITMI20132201A1 (it) * 2013-12-23 2015-06-24 Isagro Spa Processo per la sintesi regioselettiva di pirazoli
CN104974132B (zh) * 2014-04-08 2017-05-17 北大方正集团有限公司 多取代的吡啶化合物、制备方法、用途及药物组合物
SMT201900522T1 (it) 2014-05-15 2019-11-13 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metossietil)pirrolidin-3-il)-3-( 4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il )urea come inibitore della trka chinasi
PL3411360T3 (pl) * 2016-02-02 2020-08-24 Basf Se Sposób katalitycznego uwodorniania dla wytwarzania pirazoli
CN105646448B (zh) * 2016-02-03 2019-03-01 沈阳药科大学 吡啶类化合物及其用途
CN108341813B (zh) * 2017-01-24 2020-11-17 四川大学 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
BR112020012644A2 (pt) * 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. derivados de cromenopiridina como inibidores da fosfatidilinositol fosfato quinase
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11103507B2 (en) 2018-12-28 2021-08-31 Deciphera Pharmaceuticals, Llc Methods of treating disorders using CSF1R inhibitors
WO2020181197A1 (en) * 2019-03-06 2020-09-10 University Of Maryland, Baltimore Tetrameric protein scaffolds as nano-carriers of therapeutic peptides for treating cancer and other diseases
PL3966206T3 (pl) 2019-05-10 2024-01-29 Deciphera Pharmaceuticals, Llc Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
ES2966807T3 (es) 2019-05-10 2024-04-24 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y métodos de uso de los mismos
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
KR20220038696A (ko) 2019-07-19 2022-03-29 아나제네시스 바이오테크놀로지스 에스.에이.에스. 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
CA3163051A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
KR20230022457A (ko) * 2020-05-08 2023-02-15 조지아뮨 엘엘씨 Akt3 조절제
BR112023009531A2 (pt) 2020-11-18 2023-10-03 Deciphera Pharmaceuticals Llc Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
CN112830936B (zh) * 2021-01-08 2022-01-28 广西师范大学 核黄素化合物、其制备方法及应用
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
CN115772167A (zh) * 2021-09-08 2023-03-10 暨南大学 含脲结构的化合物及其应用
CN119604491A (zh) 2021-12-09 2025-03-11 德西费拉制药有限责任公司 Raf激酶抑制剂及其使用方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1115350B (de) 1959-04-17 1961-10-19 Siemens Ag Selbstschalter, insbesondere Leitungsschutz-schalter, mit einem aus einem Kniegelenk bestehenden Antriebsmechanismus fuer das Schaltorgan
GB971307A (en) 1961-03-02 1964-09-30 Wellcome Found 5-anilinopyrimidines
GB1127875A (en) 1967-03-23 1968-09-18 Parke Davis & Co 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils
US3949002A (en) * 1970-11-13 1976-04-06 Imperial Chemical Industries Limited Process for producing sulfone containing thiophenols
US3818024A (en) * 1972-02-16 1974-06-18 Velsicol Chemical Corp Benzothiazol substituted thiadiazolidines
CH565887A5 (ru) 1972-08-22 1975-08-29 Ciba Geigy Ag
US3939122A (en) * 1973-04-11 1976-02-17 Bayer Aktiengesellschaft Process for the preparation of compounds which contain hydantoin rings
FR2337554A1 (fr) 1976-01-08 1977-08-05 Buzas Andre Nouveaux derives de la pyrazolidinedione
US4093624A (en) * 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
FR2396549A2 (fr) 1977-07-06 1979-02-02 Buzas Andre Nouveaux derives de la pyrazolidinedione
US4256758A (en) 1979-06-11 1981-03-17 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4298743A (en) 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4296237A (en) * 1979-09-11 1981-10-20 Merck & Co., Inc. 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4432992A (en) * 1979-11-05 1984-02-21 Merck & Co., Inc. 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4366189A (en) 1979-12-21 1982-12-28 Ciba-Geigy Corporation 4-Heterocyclyl-4'-vinylstilbenes
JPS5915247A (ja) 1982-07-16 1984-01-26 Mitsubishi Paper Mills Ltd 画像形成方法
JPS59177557A (ja) 1983-03-28 1984-10-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US4816454A (en) * 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
AU606808B2 (en) 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5254715A (en) 1990-11-07 1993-10-19 Warner-Lambert Company Aminosulfonyl carbamates
HU214333B (hu) 1991-01-21 1998-03-02 Shionogi Seiyaku Kabushiki Kaisha Eljárás benzilidén-karbamoil-2-pirrolidon, -4-tiazolidinon, -4-oxazolidinon, -3-izotiazolidinon- és -3-izoxazolidinon-analógok és az ezeket tartalmazó gyógyszerkészítmények előállítására
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
DE4302702A1 (de) 1993-02-01 1994-08-04 Bayer Ag Arylaminosulfonylharnstoffe
AU6518694A (en) 1993-03-19 1994-10-11 Dowelanco A process for preparing halogenated isothiazoles
CA2159344A1 (en) 1993-03-30 1994-10-13 Minoru Moriwaki Cell adhesion inhibitor and thienotriazolodiazepine compound
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4337847A1 (de) 1993-11-05 1995-05-11 Bayer Ag Substituierte Phenylaminosulfonylharnstoffe
WO1995015954A1 (en) 1993-12-07 1995-06-15 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
DE4343831A1 (de) 1993-12-22 1995-06-29 Magyar Tudomanyos Akademia Substituierte Sulfonylharnstoffe
FR2715155B1 (fr) 1994-01-19 1996-07-26 Mayoly Spindler Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation.
DE4414840A1 (de) 1994-04-28 1995-11-02 Bayer Ag Substituierte Phenylaminosulfonylharnstoffe
US6096735A (en) 1994-06-15 2000-08-01 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic derivatives
US5763450A (en) 1994-11-24 1998-06-09 Hoffmann-La Roche Inc. Substituted benzyl pyrimidines
US5494925A (en) 1994-12-02 1996-02-27 Sterling Winthrop Inc. 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
WO1996019477A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Plc Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists
US5716542A (en) 1995-04-24 1998-02-10 Takasago International Corporation Liquid crystal compound and liquid crystal composition containing the same
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
GB9605945D0 (en) 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
TR199802136T2 (xx) * 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated �MPDH enzimi inhibit�rleri olarak �re t�revleri.
JPH107804A (ja) 1996-06-25 1998-01-13 Japan Synthetic Rubber Co Ltd 熱硬化性樹脂組成物
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ATE230742T1 (de) 1997-03-27 2003-01-15 Great Lakes Chemical Europ 2-(2'-hydroxphenyl)-benzotriazole und ihre verwendung als lichtschutzmittel für organische polymere
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) * 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6498274B1 (en) 1997-09-23 2002-12-24 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
IT1295933B1 (it) 1997-10-30 1999-05-28 Great Lakes Chemical Italia 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
CA2308428A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
IL136738A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase activity using substituted heterocyclic ureas
CZ299836B6 (cs) 1997-12-22 2008-12-10 Bayer Corporation Aryl- a heteroaryl-substituované heterocyklické mocoviny, jejich použití a farmaceutické kompozice s jejich obsahem
EP1043995B9 (en) 1997-12-22 2008-10-08 Bayer Pharmaceuticals Corp. INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
DE1047418T1 (de) 1997-12-22 2001-05-03 Bayer Corp., Pittsburgh Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
EP0928790B1 (en) * 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
ATE234099T1 (de) 1998-04-24 2003-03-15 Leuven K U Res & Dev Immununterdrückende effekte von 8 substituierten xanthinderivaten
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2000275886A (ja) 1999-03-23 2000-10-06 Konica Corp 電子写真感光体、それを用いたプロセスカートリッジ及び画像形成装置
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6500628B1 (en) * 2000-05-25 2002-12-31 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
CN1308310C (zh) * 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
JP2004518739A (ja) * 2001-02-15 2004-06-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤として有用なヘテロアリール置換尿素化合物の合成方法
CA2439263C (en) * 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
CA2441455A1 (en) 2001-03-23 2002-10-03 Merck Sharp & Dohme Limited Imidazo-pyrimidine derivatives as ligands for gaba receptors
EP1281399A3 (en) 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
JP2005503400A (ja) 2001-09-13 2005-02-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介病の治療方法
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
JP4629978B2 (ja) * 2002-02-25 2011-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物
AR037647A1 (es) * 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
AU2003246927A1 (en) 2002-07-03 2004-01-23 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
US20040138216A1 (en) 2002-12-23 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
US20080045531A1 (en) 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP4927533B2 (ja) * 2003-02-28 2012-05-09 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な置換ピリジン誘導体
WO2004113352A1 (en) 2003-06-19 2004-12-29 Amedis Pharmaceuticals Ltd. Silylated heterocyclylurea derivatives as cytokine-inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050165031A1 (en) * 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
AU2005325676A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080248487A1 (en) 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
US20080248548A1 (en) 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
WO2008140895A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases

Also Published As

Publication number Publication date
JP2010524974A (ja) 2010-07-22
MX2009011343A (es) 2009-11-05
WO2008131227A1 (en) 2008-10-30
AU2008242720A1 (en) 2008-10-30
AU2008242767A1 (en) 2008-10-30
AU2008242697A1 (en) 2008-10-30
WO2008131276A1 (en) 2008-10-30
BRPI0810094A2 (pt) 2014-10-21
RU2009142851A (ru) 2011-05-27
CN101878031A (zh) 2010-11-03
EP2481736A1 (en) 2012-08-01
CA2684666A1 (en) 2008-11-20
CN101801383A (zh) 2010-08-11
CA2684950A1 (en) 2008-10-30
JP2010524970A (ja) 2010-07-22
WO2008140895A1 (en) 2008-11-20
CA2684949A1 (en) 2008-10-30
BRPI0807717A2 (pt) 2014-05-20
AU2008251723A1 (en) 2008-11-20
EP2146718A4 (en) 2010-08-11
US8143293B2 (en) 2012-03-27
WO2008131253A1 (en) 2008-10-30
EP2146717A4 (en) 2010-08-11
US20080269254A1 (en) 2008-10-30
CA2678639A1 (en) 2008-10-30
MX2009009066A (es) 2009-09-02
EP2146716A1 (en) 2010-01-27
EP2146717A1 (en) 2010-01-27
KR20100014811A (ko) 2010-02-11
US20080269267A1 (en) 2008-10-30
SG183054A1 (en) 2012-08-30
US20080261965A1 (en) 2008-10-23
EP2146718A1 (en) 2010-01-27
US20080261961A1 (en) 2008-10-23
KR20100017184A (ko) 2010-02-16
EP2148677A4 (en) 2010-08-11
IL201650A0 (en) 2010-05-31
EP2146716A4 (en) 2010-08-11
EP2148677A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
EA200970700A1 (ru) Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
EA201170627A1 (ru) Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
WO2013036232A3 (en) Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
Wu et al. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance
Ségaliny et al. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Roskoski Jr ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
CY1116231T1 (el) ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ
CY1118730T1 (el) Παραγωγα πυριδινης ως αναστολεις της αναδιαταχθεισας κατα την διαρκεια διαλοιμωξης (ret) κινασης
FI3514151T3 (fi) Proteiinikinaasi c:n estäjiä ja niiden käyttötapoja
JP2010501572A5 (ru)
RU2015128606A (ru) Производные азаиндола в качестве ингибиторов протеинкиназ
RU2014125230A (ru) Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность
BRPI0716981B8 (pt) inibidores de cinase úteis para tratamento de doenças proliferativas, e composição farmacêutica
RU2012151012A (ru) Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
RU2017131430A (ru) Способ лечения рака, ассоциированного с мутацией ras
El-Azab et al. Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3, 4, 5-trimethoxybenzyl)-4 (3H)-quinazolinone analogues
EA201492004A1 (ru) Органические композиции для лечения kras-ассоциированных заболеваний
JP2008513366A5 (ru)
JP2017514806A5 (ru)
JP2018536682A5 (ru)
RU2016112421A (ru) Протиоопухолевое средство и усилитель противоопухолевого эффекта
Hyman et al. Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2" basket" study
Lategahn et al. Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach